Danaher Corp

U.S. equity futures declined Tuesday amid AI disruption fears and geopolitical focus. For novice investors, the backdrop features falling fund costs but rising market uncertainty.

Thermo Fisher Scientific shares declined 0.98% to $504.82 on Friday, extending a recent downturn. The company has raised $3.8 billion in senior notes to partially fund its acquisition of clinical data firm Clario.

Danaher shares dropped 1.1% Friday, continuing a two-session decline. Trading volume was active as markets prepare for a holiday closure and a data-heavy week ahead.

Thermo Fisher Scientific raised $3.8 billion through a multi-tranche bond offering to fund its planned Clario acquisition. Shares closed down nearly 1% on Friday.

Danaher shares fell in extended trading Friday, closing near $212.58. The dip precedes a market holiday, with attention shifting to next week's key inflation report.

Thermo Fisher Scientific shares edged higher Monday after filing a preliminary prospectus for a four-part senior notes offering to fund its planned Clario acquisition. The company reported consolidated debt of $39.38 billion as of December 31, 2025.

Thermo Fisher Scientific closed Friday at $542.83, down 6.7% for the week as investors weigh pressure from academic research funding cuts. The company's 2026 outlook projects adjusted earnings of $24.22 to $24.80 per share.

Thermo Fisher Scientific's stock held near $543 Friday following a sharp decline. The company plans to close a Massachusetts facility by 2026, affecting 80 jobs, while investors await key U.S. economic reports.